Jump to Main Contents

Home > Division of Cancer RNA Research

Division of Cancer RNA Research

News

Oct. 6, 2025
Our lab website has reached over 50,000 page views! Thank you all for your interest and support!
Oct. 5, 2025
Akihide Yoshimi received the Growth Vision Award at the JST FOREST Panel meeting!
Sep. 30, 2025
Akihide Yoshimi was invited to speak at the Tsuruoka Conference 2025.
Sep. 26, 2025
Asuka Kawachi gave an oral presentation at the 84th JCA Annual Meeting!
Sep. 26, 2025
Kensuke Hirosuna delivered an oral talk at the 84th JCA Annual Meeting!
Sep. 26, 2025
Akihide Yoshimi was invited to speak at the 84th JCA Annual Meeting.
Sep. 26, 2025
Masahiko Ajiro gave an oral presentation at the 84th JCA Annual Meeting!
Sep. 26, 2025
Moritoshi Sakamoto presented a poster at the 84th JCA Annual Meeting!
Sep. 25, 2025
Tomoya Muto gave an invited lecture at the 84th JCA Annual Meeting!
Sep. 17, 2025
Akihide Yoshimi gave an invited lecture at the C8 - Allan Slaight Breakthrough Forum in Toronto.
more

Our Research Interest


Our studies have been focused on how RNA processing including RNA splicing is altered in cancer and functionally drives cancer initiation and maintenance. The advent of high-throughput transcriptome sequencing has provided a wealth of information on RNA splicing on a genome-wide scale. It is now understood that > 95% of human genes are subject to alternative splicing. RNA splicing is considered to be a major mediator of proteome diversity through its ability to generate multiple transcripts with differing amino acid sequences from a single gene. The discovery of recurrent mutations in components of the RNA-splicing machinery in 2011 further highlighted the importance of aberrant splicing in cancer as well as a potential therapeutic vulnerability for cells bearing these mutations. Despite the major advances in our understanding of the genomics, molecular biology and therapeutic implications of altered RNA processing in cancer, the full contribution of aberrant RNA splicing to cancer pathogenesis has not been fully elucidated. Our aim is to contribute to the full understanding of the pathogenic roles of altered RNA processing in a variety of cancers and to the development of therapeutically efficacious and safe strategies to improve the outcome of cancer patients.
wordle2.png
(Figure was made by using Wordle based on our recent papers)